Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy.

Satoru Nakayama, Kentaro Nakayama, Yuji Takebayashi, Kohkichi Hata, Ritsuto Fujiwaki, Manabu Fukumoto, Kohji Miyazaki

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


We analyzed a series of ovarian carcinomas from patients treated with cisplatin-based chemotherapy for loss of heterozygosity (LOH) to determine the relationship between microsatellite alteration and prognosis. Patients with tumors that had lost alleles at loci 3p14-21, 12qter, or 17p13.3 showed significantly reduced survival compared to patients with tumors that retained both alleles at those loci. The 5-year mortality rates for patients exhibiting allele loss and patients with allele retention were 50 and 41%, respectively, for the 3p14-21 locus (P=0.0023); 57 and 24%, respectively, for 12qter (P=0.0256); and 55 and 40%, respectively, for 17p13.3 (P=0.0489). A statistically significant difference was also observed with respect to fractional allelic loss (FAL), which was a significant indicator for disease recurrence (P=0.0227). The prognosis of patients with high FAL values were significantly worse compared to those with low FAL values (P=0.0306). Our results suggested that LOH at loci 3p14-21, 12qter, or 17p13.3 was a significant predictor of poor survival in ovarian carcinomas treated with cisplatin-based chemotherapy. Furthermore, the association of FAL value with therapy response indicated that ovarian carcinomas with high levels of chromosomal alteration may be more resistant to this type of chemotherapy.

Original languageEnglish
Pages (from-to)621-625
Number of pages5
JournalInternational journal of molecular medicine
Issue number5
Publication statusPublished - 2003 May

ASJC Scopus subject areas

  • Genetics


Dive into the research topics of 'Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy.'. Together they form a unique fingerprint.

Cite this